Image 01
Rivastigmine Patch, Extended Release
Product Images NDC 0781-7313
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Rivastigmine (NDC 0781-7313). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Sandoz Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image 02
Image 03
The text indicates the concentration of Rivastigmine in ng/mL for different dosages administered over a period of 24 hours. There were three groups of participants: one group received 13.3 mg/24 hours (n=19), one group received 9.5 mg/24 hours (n=22), and one group received 4.6 mg/24 hours (n=22). The concentration of Rivastigmine was measured and found to be 8 ng/mL or higher for the group receiving the highest dosage.*
Image 04
Image 05
This appears to be a medication dosing chart with various doses listed in milligrams per 24 hours. It also includes a reference to a placebo and a rating scale called ADCS-CGIC. The last line contains non-English characters and cannot be interpreted.*
Image 06
The text describes two types of Rivastigmine Transdermal System, one with a dosage of 13.3 mg/24hr and the other with 0.5 mg/2éhr. The text also includes a chart showing ADCS-IADL change from baseline and weeks of treatment. The chart reveals that there is a statistically significant difference between the two dosages of the Transdermal System, with the 13.3 mg/24hr dosage showing clinical improvement.*
Image 07
This document appears to be a clinical study report on the effectiveness of two dosages (13.3 mg/24h and 9.5 mg/24h) of the Rivastigmine Transdermal System in improving cognitive function as measured by the ADAS-Cog test. The report shows a significant improvement in ADAS-Cog scores for the 13.3 mg/24h dosage compared to the 9.5 mg/24h dosage.*
Image 08
Image 09
This is a clinical study evaluating the improvement of patients after treatment with Rivastigmine patch. The analysis shows LS mean diff. improvement, with corresponding values and levels of statistical significance. The study lasted for 700 days with a decline observed after 8 weeks of treatment. The LS mean and standard error values were adjusted for pooled center and baseline.*
Image 10
Image 11
This appears to be a list of body parts with certain locations specified, including the left or right upper arm, left or right side of chest, side, left or right upper back, and left or right lower back. This information may be useful for identifying specific areas of pain or discomfort.*
Image 12
Image 13
Protective liners refers to materials that are designed to provide a protective layer for a surface or object. The given text only mentions "Sticky surface of patch" which provides no context and is not clear which type of patch or what material is being referred to. Hence, a useful description cannot be generated with this text.*
Image 14
Image 15
Image 16
Image 17
This is a set of instructions to safely dispose of a slide folded patch. First, you should place the patch in the trash. Then, you need to fold the sticky sides of the patch together into an empty pouch that you saved. It is important to keep this pouch away from children and pets.*
Image 18
Image 19
Image 20
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
